{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"13"}],"units":"Participants"}],"description":"The DLTs were defined as any which included Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or Grade 4 neutropenia continuing for greater than equal to (\\>=) 7 consecutive days, non-hematological toxicity of Grade 3 or higher (excluding transient electrolyte abnormalities, diarrhea, nausea, and vomiting that recovers to Grade 2 or lower with appropriate treatment and participants having Grade 2 aspartate transaminase (AST) and/or alanine transaminase (ALT) at baseline must have Grade 3 AST/ALT for 7 days or Grade 4 AST/ALT to be considered a DLT), and adverse events (AEs) that required suspension of treatment for a total of \\>=7 days which the Investigator could not rule out as been related to alectinib.","groups":[{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 or 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib 300 mg (Fasted): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG001","title":"Alectinib 460 mg (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG002","title":"Alectinib 600 mg (Fed): Phase I (20/40/150 mg)"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG003","title":"Alectinib 760 mg (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG004","title":"Alectinib 900 mg (Fed): Phase I (20/40/150 mg)"}],"paramType":"NUMBER","populationDescription":"Phase I safety population","reportingStatus":"POSTED","timeFrame":"Throughout Cycle 1 of Phase I (21 days)","title":"Number of Participants With Dose Limiting Toxicities (DLTs): Phase I","type":"PRIMARY","unitOfMeasure":"participants"}